Volume 5.31 | Aug 22

Prostate Cell News 5.31 August 22, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
The Expression of Glucocorticoid Receptor Is Negatively Regulated by Active Androgen Receptor Signaling in Prostate Tumors
Investigators applied prostate cancer (PCa) tissue microarrays to show that glucocorticoid receptor protein levels were elevated by castration therapy, but reduced to pre-castration levels when tumors were at the castration-resistant PCa stage. [Int J Cancer] Abstract
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Phorbol Ester Stimulates Ethanolamine Release from the Metastatic Basal Prostate Cancer Cell Line PC3 but Not from Prostate Epithelial Cell Lines LNCaP and P4E6
Scientists investigated whether tumorigenesis in cancer-derived prostate epithelial cell lines influences protein kinase C-linked turnover of ethanolamine phosphoglycerides and alters the pattern of ethanolamine metabolites released to the medium. [Br J Cancer] Abstract

Breaking Immune Tolerance by Targeting CD25+ Regulatory T Cells Is Essential for the Anti-Tumor Effect of the CTLA-4 Blockade in an HLA-DR Transgenic Mouse Model of Prostate Cancer
Researchers studied the effect of CD25+ cell depletion and CTLA-4 blockade on the growth of transgenic mouse adenocarcinoma of prostate-PSA tumor cells in DR2bxPSA F1 mice. In these mice, immunological tolerance to PSA was established in a context of the HLA-DRB1*1501(DR2b) allele. [Prostate] Abstract

Snail Regulated by PKC/GSK-3β Pathway Is Crucial for EGF-Induced Epithelial-Mesenchymal Transition (EMT) of Cancer Cells
Scientists demonstrate that epidermal growth factor (EGF) can induce EMT in human prostate and lung cancer cells and thus promote invasion and migration. EGF-induced EMT has been characterized by the cells acquiring mesenchymal spindle-like morphology and increasing their expression of N-cadherin and fibronectin, with a concomitant decrease of E-cadherin. [Cell Tissue Res] Abstract

Down-Regulation of Dicer and Ago2 Is Associated with Cell Proliferation and Apoptosis in Prostate Cancer
Dicer and Argonaute2 (Ago2) are critical components responsible not only for RNA interference but also for microRNA synthesis. Researchers investigated the roles of Dicer and Ago2 in prostate cancer. [Tumor Biol] Abstract

A Therapeutic Approach to Treat Prostate Cancer by Targeting Nm23-H1/h-Prune Interaction
Using a mouse orthotopic model with bioluminescent imaging, scientists show evidences that competitive permeable peptide reduces prostate cancer metastases formation. [Naunyn Schmiedebergs Arch Pharmacol] Abstract

Cytotoxic Effects of Escin on Human Castration-Resistant Prostate Cancer Cells through the Induction of Apoptosis and G2/M Cell Cycle Arrest
Investigators evaluate the in vitro and in vivo effects of escin on human castration-resistant prostate cancer (CRPC) cells, PC-3 and DU-145. The in vivo efficacy of escin in CRPC cells was assessed using a xenograft tumor model subcutaneously established in BALB/c nude mice. [Urology] Abstract

Lyn Tyrosine Kinase Regulates Androgen Receptor Expression and Activity in Castrate-Resistant Prostate Cancer
Researchers report that Lyn tyrosine kinase expression is upregulated in Castrate-resistant prostate cancer (CRPC) human specimens compared with hormone naive or normal tissue. Lyn overexpression enhanced androgen receptor transcriptional activity both in vitro and in vivo and accelerated CRPC. [Oncogenesis]
Full Article

CLINICAL RESEARCH

Short-Term Androgen Suppression and Radiotherapy versus Intermediate-Term Androgen Suppression and Radiotherapy, with or without Zoledronic Acid, in Men with Locally Advanced Prostate Cancer (TROG 03.04 RADAR): An Open-Label, Randomized, Phase III Factorial Trial
Researchers investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than six months of neoadjuvant androgen suppression plus radiotherapy with or without zoledronic acid. [Lancet Oncol] Abstract

Enzalutamide in European and North American Men Participating in the AFFIRM Trial
Investigators explored differences in efficacy and safety outcomes between European and North American patients in the AFFIRM trial. AFFIRM is Phase III, double-blind, placebo-controlled, multinational trial in men with metastatic castration-resistant prostate cancer after docetaxel.[BJU Int] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
DNA Damage Response and Prostate Cancer: Defects, Regulation and Therapeutic Implications
The authors discuss specific DNA damage response (DDR) defects in prostate cancer that occur during disease progression to summarize recent advances in understanding the regulation of DDR in prostate cancer, and to present potential therapeutic opportunities through combinational targeting of the intact components of DDR signaling pathways. [Oncogene] Abstract

NUMB Inhibition of NOTCH Signaling as a Therapeutic Target in Prostate Cancer
NUMB (protein numb homologue), a key regulator of cell fate, represents an attractive, actionable target in prostate cancer. NUMB participates in the observed deregulation of NOTCH (neurogenic locus notch homologue protein) signaling in prostate tumors, and the NUMB-NOTCH interaction regulates cell fate. [Nat Rev Urol] Abstract

Autophagy as a Modulator and Target in Prostate Cancer
Autophagy can promote greater cellular robustness in the context of therapeutic intervention. In advanced prostate cancer, preclinical data provide evidence that autophagy facilitates both disease progression and therapeutic resistance. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414
MorphoSys AG and Emergent BioSolutions Inc. announced an agreement for the joint development and commercialization of ES414. The compound, to be renamed MOR209/ES414, is an anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer, which was developed by Emergent using its proprietary ADAPTIR™ (modular protein technology) platform. [MorphoSys AG] Press Release

Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Bristol-Myers Squibb Company and Celgene Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, OPDIVO, and Celgene’s nab® technology-based chemotherapy ABRAXANE®, in a Phase I study. [Bristol-Myers Squibb Company] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 21st Cell Symposia – Hallmarks of Cancer: Asia
November 9-11, 2014
Beijing, China

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Bioinformatics Analyst / Computational Biologist – Molecular Analysis of Prostate Cancer (Cornell University)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Position – Molecular Physiology in Prostate Cancer (Duke Molecular Physiology Institute)

Senior Researcher – Interactions between Signaling Pathways of Cytokines, Growth Factors and Androgen Receptors (International Clinical Research Center – St. Anne’s University Hospital)

Postdoctoral Fellow – Cancer and miR Biology (Thomas Jefferson University Hospital)

PhD Position – Prostate Cancer Research (Institute of Oncology Research)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us